Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment

<div>CD20 expression in the LN. The patient underwent lymph node (LN) biopsy. (a) After the operation, LN was grinded to prepare LN suspension. The lymphocytes of LN and peripheral blood (PB) were stained for CD2, CD3, CD5, CD7, HLA-DR, CD10, CD34, CD8, CD23, FMC7, CD79b, CD79a, CyCD3, and CD20. A representative flow pattern of CD20 was shown. (b) Further confirmation of CD20 expression in pathology slides. The pathology slides were stain of anti-CD20 by standard immunohistochemistry staining. Pathology was shown before and after HSCT separately (100x and 400x).</div>

Case Reports in Hematology

fig2

Figure 2

Figure 2: Lymph Node Flow Cytometry as a Prompt Recognition of Ultra Early Onset PTLD: A Successful Case of Rituximab Treatment 